Stocks · Health care · Biological Products, (No Diagnostic Substances)

aTYR PHARMA INC

ATYR Clue Score30

United States Fiscal year ends December CIK 0001339970 Results filed 5 Nov 2026

Add to watchlist

What the insiders did Net buying

By person

13 insiders · 80 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Paul Schimmel

Director

$5.69M (21)

$30.74K (1)

+$5.66M

1,217,176

1.24%

$604.08K

—

EcoR1 Capital Fund Qualified, L.P. entity

10% owner

$143.33K (2)

$3.06M (7)

−$2.91M

0

0.0000%

$0.00

−100.0%

John Mendlein

Director

$362.94K (7)

—

+$362.94K

615,382

0.6274%

$305.41K

+135.8%

Sanjay Shukla

President and CEO

$286.25K (12)

$12.62K (3)

+$273.63K

153,553

0.1565%

$76.21K

+61,321%

Timothy Coughlin

Director

$87.50K (1)

—

+$87.50K

56,000

0.0571%

$27.79K

—

Jill Marie Broadfoot

Chief Financial Officer

$101.65K (6)

$17.14K (6)

+$84.51K

37,296

0.0380%

$18.51K

—

John K Clarke

Director

—

$72.06K (5)

−$72.06K

127,880

0.1304%

$63.47K

−8.3%

Ashraf Amanullah

See Remarks

$24.75K (1)

$4.77K (1)

+$19.98K

26,264

0.0268%

$13.03K

+162.7%

Jane A Gross

Director

$15.00K (1)

—

+$15.00K

9,750

0.0099%

$4.84K

—

John T Blake

Senior Vice President, Finance

—

$4.77K (1)

−$4.77K

1,932

0.0020%

$958.85

—

Nancy Denyes

General Counsel

$9.28K (1)

$7.75K (4)

+$1.53K

33,124

0.0338%

$16.44K

+201.9%

Svetlana Lucas

Director

—

—

—

6,000

0.0061%

$2.98K

—

Sara Zaknoen

Director

—

—

—

6,000

0.0061%

$2.98K

—